Sign in
Download Opera News App

BIONTECH

Pfizer says third dose of vaccine could boost protection against Delta

Athird dose of the Pfizer vaccine could “strongly” boost protection against the Delta variant, according to claims made by the firm and its partner BioNTech. The findings, which have not been peer reviewed, were revealed as the firm announced plans to seek regulatory approval for booster jabs.

standard.co.uk ,  2d 0
Pfizer says third dose of vaccine could boost protection against Delta

Pfizer vaccine side effects: Eight 'very common' side effects of the Pfizer Covid vaccine

PFIZER vaccines have been handed out to millions of people in the UK as an alternative to the AstraZeneca and Moderna jabs. But what are the Pfizer vaccine side effects? These are the eight "very common" side effects of the Covid vaccine you should watch out for, including headaches and tiredness.

express.co.uk ,  3d 562
Pfizer vaccine side effects: Eight 'very common' side effects of the Pfizer Covid vaccine

Pfizer vaccine ‘protective for at least six months’

The new data comes from a 44,000-person study. The effectiveness of the Pfizer vaccine wanes slightly over time but it remains strongly protective for at least six months after the second dose, according to company data. The findings are one piece of evidence that US health authorities will consider in deciding if and when booster doses might be needed.

guernseypress.com ,  4d 68
Pfizer vaccine ‘protective for at least six months’

Pfizer hikes Covid vaccine sales forecast by almost a third to $33.5bn

Pfizer has raised its full-year sales forecast for its coronavirus vaccine by nearly a third, as governments across the world rush to secure doses to vaccinate their populations. The US drugmaker raised its 2021 forecast for sales of the Covid vaccine that it produces with Germany’s BioNTech by 28.8 per cent to $33.5bn (£24bn), up from the $26bn it had projected in the previous quarter.

cityam.com ,  4d 7
Pfizer hikes Covid vaccine sales forecast by almost a third to $33.5bn

AC Immune lures BioNTech investors, buys Parkinson's vaccine candidate

ZURICH, July 27 (Reuters) - AC Immune has gained a multi-million investment from main backers of German COVID-19 vaccine developer BioNTech while acquiring a possible Parkinson's disease vaccine, the Swiss biotech group said on Tuesday. It announced a $25 million private share placement with a group of investors led by Athos Service GmbH - the vehicle set up by billionaires Andreas and Thomas Struengmann and which is one of the lead investors in BioNTech.

mobile.reuters.com ,  5d 0
AC Immune lures BioNTech investors, buys Parkinson's vaccine candidate

German group BioNTech behind first Covid jab aims to develop effective malaria vaccine

The German pharmaceutical group behind one of the most successful Covid vaccines hopes to use the same technology to develop a vaccine against malaria - one of the world’s deadliest diseases. BioNTech, which developed the first coronavirus vaccine with US company Pfizer, is aiming to begin clinical trials for a "safe and highly effective malaria vaccine".

itv.com ,  5d 4
German group BioNTech behind first Covid jab aims to develop effective malaria vaccine

Mandatory vaccines for students to attend lectures ‘hugely discriminatory’, universities union says

The Independent’s journalism is supported by our readers. When you purchase through links on our site, we may earn commission. University and College Union accuses PM of ‘trying to pin blame on students for not yet taking up a vaccine they haven’t been prioritised to receive’

independent.co.uk ,  6d 0
Mandatory vaccines for students to attend lectures ‘hugely discriminatory’, universities union says

BioNTech aims to develop mRNA-based malaria vaccine

Plans to start clinical trial by end of 2022 Malaria kills more than 400,000 people per year BioNTech explores vaccine production in Africa BERLIN, July 26 (Reuters) - BioNTech (22UAy.DE) wants to build on its success in COVID-19 by developing the first vaccine for malaria based on mRNA technology and aims to start clinical testing by the end on 2022, in an attempt to eradicate the mosquito-borne illness.

reuters.com ,  6d 0
BioNTech aims to develop mRNA-based malaria vaccine

Mixed AstraZeneca-Pfizer shot boosts COVID antibody level - study

SEOUL (Reuters) - A mixed vaccination of first AstraZeneca and then a Pfizer COVID-19 shot boosted neutralizing antibody levels by six times compared with two AstraZeneca doses, a study from South Korea showed. The study involved 499 medical workers - 100 receiving mixed doses, 200 taking two doses of the Pfizer/BioNTech shot and the remainder getting two AstraZeneca shots.

mobile.reuters.com ,  6d 0
Mixed AstraZeneca-Pfizer shot boosts COVID antibody level - study

Vaccine maker BioNTech to use mRNA tech to target malaria

Pharmaceutical company BioNTech says it wants to use the mRNA technology behind its coronavirus vaccine to target malaria Pharmaceutical company BioNTech said Monday that it wants to use the mRNA technology behind its coronavirus vaccine to target malaria. The Germany-based company, which developed the first widely approved coronavirus shot together with U.S. partner Pfizer aims to begin clinical trials for a “safe and highly effective malaria vaccine” by the end of next year.

independent.co.uk ,  6d 0
Vaccine maker BioNTech to use mRNA tech to target malaria

Covid-19 vaccines: eight week gap between Pfizer jabs a ‘sweet spot’ for boosting immunity

Ideal period of two months between doses is reassuring news for the millions of people urged to bring forward their appointment earlier than 12-week recommendation. An eight-week gap between the first and second doses of the Pfizer/BioNTech Covid-19 vaccine is a “sweet spot” when it comes to generating strong immune response while protecting the UK population against the Delta variant of coronavirus, scientists have said.

inews.co.uk ,  10d 0
Covid-19 vaccines: eight week gap between Pfizer jabs a ‘sweet spot’ for boosting immunity

German Pharma-Park Marburg, home to BioNTech, up for sale -sources

(Reuters) - Pharma-Park Marburg, where German drugmaker BioNTech produces its COVID-19 vaccine, has been put up for sale in a potential 450 million euro ($531 million) deal, three people close to the matter said. The biotech-focused industrial park, which also counts GSK, Healthineers and CSL Behring as tenants, has been offered for sale by its owner Infrareal, they said.

mobile.reuters.com ,  10d 0
German Pharma-Park Marburg, home to BioNTech, up for sale -sources

South African firm to help make Pfizer/BioNTech COVID vaccine

July 21 (Reuters) - Pfizer and BioNTech have struck a deal for South Africa's Biovac Institute to help manufacture around 100 million doses a year of their COVID-19 vaccine for the African Union, the firms said on Wednesday. The deal is to "fill and finish" the vaccine, the final stages of manufacturing where the product is processed and put into vials.

dailymail.co.uk ,  11d 1
South African firm to help make Pfizer/BioNTech COVID vaccine